Literature DB >> 9326230

Bernard-Soulier syndrome caused by a dinucleotide deletion and reading frameshift in the region encoding the glycoprotein Ib alpha transmembrane domain.

V Afshar-Kharghan1, J A López.   

Abstract

We investigated the molecular genetic and biosynthetic basis of Bernard-Soulier syndrome in a severely affected white woman. Flow cytometric analysis showed a severe deficiency of glycoprotein (GP) Ib, GP IX, and GP V on the surface of her platelets. Similarly, GP Ib alpha was undetectable by immunoblot analysis of platelet lysates. Surprisingly, a large quantity of a 70-kD protein (which probably represents a GP Ib alpha degradation product) was found in the patient's plasma in much greater quantities than in the plasma of an unaffected individual. To analyze the molecular lesion responsible for the disorder, we amplified and sequenced gene segments corresponding to the entire coding regions of the GP Ib alpha, GP Ib beta, and GP IX genes. The patient was homozygous for a specific GP Ib alpha allele that contained two tandem VNTR repeats in the region encoding the macroglycopeptide (C variant) and three differences from the published GP Ib alpha gene sequence. Two mutations were unlikely to be involved in the disorder: the substitution of a single base (T --> C) in the second nucleotide of exon 2, which is in the 5' untranslated region of the GP Ib alpha transcript, and a silent mutation in the third base of the codon for Arg342 (A --> G) that does not change the amino acid sequence. The third mutation was a deletion of the last two bases of the codon for Tyr492 (TAT). This mutation causes a frameshift that alters the GP Ib alpha amino acid sequence, beginning within its transmembrane region. The mutant polypeptide contains 81 novel amino acids and is 38 amino acids shorter than its wild-type counterpart. The new sequence changes the hydrophobic nature of the transmembrane domain and greatly decreases the net positive charge of what had been the cytoplasmic domain. The deletion mutation was introduced into the GP Ib alpha cDNA, alone and in combination with the 5' mutation, and expressed in Chinese hamster ovary (CHO) cells. The deletion alone severely reduced GP Ib alpha expression on the cell surface. Expression was not decreased further by addition of the 5' mutation, confirming that the deletion was the cause of the Bernard-Soulier phenotype. Stable cell lines expressing the mutant polypeptide secreted large amounts of the polypeptide into the medium, suggesting that the mutant anchors poorly in the plasma membrane. Nevertheless, a fraction of the mutant was able to associate with GP Ib beta, as demonstrated by their coimmunoprecipitation with a GP Ib beta antibody.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9326230

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Biosynthesis and intracellular post-translational processing of normal and mutant platelet glycoprotein GPIb-IX.

Authors:  P Ulsemer; C Strassel; M J Baas; J Salamero; S Chasserot-Golaz; J P Cazenave; C De La Salle; F Lanza
Journal:  Biochem J       Date:  2001-09-01       Impact factor: 3.857

Review 2.  Genetic abnormalities of Bernard-Soulier syndrome.

Authors:  Shinji Kunishima; Tadashi Kamiya; Hidehiko Saito
Journal:  Int J Hematol       Date:  2002-11       Impact factor: 2.490

3.  Specific heteromeric association of four transmembrane peptides derived from platelet glycoprotein Ib-IX complex.

Authors:  Shi-Zhong Luo; Renhao Li
Journal:  J Mol Biol       Date:  2008-07-22       Impact factor: 5.469

4.  Correction of murine Bernard-Soulier syndrome by lentivirus-mediated gene therapy.

Authors:  Sachiko Kanaji; Erin L Kuether; Scot A Fahs; Jocelyn A Schroeder; Jerry Ware; Robert R Montgomery; Qizhen Shi
Journal:  Mol Ther       Date:  2011-11-01       Impact factor: 11.454

Review 5.  Bernard-Soulier syndrome (hemorrhagiparous thrombocytic dystrophy).

Authors:  François Lanza
Journal:  Orphanet J Rare Dis       Date:  2006-11-16       Impact factor: 4.123

6.  Novel Compound Heterozygous Mutations in Two Families With Bernard-Soulier Syndrome.

Authors:  Milen Minkov; Petra Zeitlhofer; Andreas Zoubek; Leo Kager; Simon Panzer; Oskar A Haas
Journal:  Front Pediatr       Date:  2021-01-22       Impact factor: 3.418

7.  Abnormal whole blood thrombi in humans with inherited platelet receptor defects.

Authors:  Francis J Castellino; Zhong Liang; Patrick K Davis; Rashna D Balsara; Harsha Musunuru; Deborah L Donahue; Denise L Smith; Mayra J Sandoval-Cooper; Victoria A Ploplis; Mark Walsh
Journal:  PLoS One       Date:  2012-12-28       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.